These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18414863)

  • 1. Cytogenetic features in myelodysplastic syndromes.
    Haase D
    Ann Hematol; 2008 Jul; 87(7):515-26. PubMed ID: 18414863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic abnormalities in myelodysplastic syndrome: an overview.
    Kawankar N; Vundinti BR
    Hematology; 2011 May; 16(3):131-8. PubMed ID: 21669051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosomal aberrations in myelodysplastic syndrome].
    Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
    Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes.
    Billström R; Thiede T; Hansen S; Heim S; Kristoffersson U; Mandahl N; Mitelman F
    Eur J Haematol; 1988 Oct; 41(4):341-6. PubMed ID: 3197821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic findings in 179 patients with myelodysplastic syndromes.
    Haase D; Fonatsch C; Freund M; Wörmann B; Bodenstein H; Bartels H; Stollmann-Gibbels B; Lengfelder E
    Ann Hematol; 1995 Apr; 70(4):171-87. PubMed ID: 7748962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
    Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
    Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
    Kantarjian H; O'Brien S; Ravandi F; Borthakur G; Faderl S; Bueso-Ramos C; Abruzzo L; Pierce S; Shan J; Issa JP; Garcia-Manero G
    Cancer; 2009 Nov; 115(22):5202-9. PubMed ID: 19691096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
    Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
    Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment options: impact of cytogenetics on the course of myelodysplasia.
    Galili N; Cerny J; Raza A
    Curr Treat Options Oncol; 2007 Apr; 8(2):117-28. PubMed ID: 17634837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
    J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
    Ganster C; Müller-Thomas C; Haferlach C; Strupp C; Ogata K; Germing U; Hildebrandt B; Mallo M; Lübbert M; Müller C; Solé F; Götze KS; Vandenberghe P; Göhring G; Steinmetz T; Kröger N; Platzbecker U; Söling U; Raynaud S; Shirneshan K; Schanz J; Haase D
    Genes Chromosomes Cancer; 2019 Oct; 58(10):689-697. PubMed ID: 30994215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics.
    Trost D; Hildebrandt B; Müller N; Germing U; Royer-Pokora B
    Leuk Res; 2004 Feb; 28(2):171-7. PubMed ID: 14654082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
    Jung SW; Lee SY; Jekarl DW; Kim M; Lim J; Kim Y; Han K; Kim YJ; Cho SG; Song J
    Leuk Res; 2011 Jun; 35(6):735-40. PubMed ID: 21146871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.